Skip to content

A study on the detection of circulating tumor cells (CTC) in patients with resected pulmonary metastases from colorectal cancer and its clinical significance as a biomarker

A study on the detection of circulating tumor cells (CTC) in patients with resected pulmonary metastases from colorectal cancer and its clinical significance as a biomarker - CTC detection in patients with resected pulmonary metastases from colorectal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017460
Enrollment
5
Registered
2015-05-08
Start date
2012-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary metastases from colorectal cancer

Interventions

Peripheral blood samples will be drawn from CRC patients with PM prior to operation and will be tested for CTC enumeration.

Sponsors

Kawasaki Medical School, Department of General Thoracic Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with metachronous PM after complete resection of CRC (cancer of the colon, cancer of the rectum) in whom the metastatic lesions are judged to be completely resectable 2. Patients with no evidence of non-PM including resectable hepatic metastasis and with no history of treatment of metastasis 3. Patients with adequate major organ functions and with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 who are judged capable of tolerating a major operation 4. Patients who personally have given informed consent in writing

Exclusion criteria

Exclusion criteria: 1. History of pulmonary resection or lung radiofrequency ablation (RFA) / radiation therapy at the time of enrollment 2. Serious drug allergy 3. Chest X-ray evidence of interstitial pneumonia or pulmonary fibrosis 4. Any or suspected intercurrent active infection 5. Pregnant women, nursing mothers, possibly pregnant women, and women with no intention of practicing contraception 6. Ongoing continuous treatment with systemic corticosteroid medication 7. Poorly controlled diabetes mellitus or any serious complication such as a cardiac disorder 8. History of active double cancer *Except for malignancies clinically judged to be non-invasive cancer such as carcinoma in situ *Except for malignancies which have not recurred in >5 years after radical treatment 9. Patients likely to be unable to personally give written informed consent and any other condition that the investigator feels would be inadequate for the safe conduct of this study

Design outcomes

Primary

MeasureTime frame
CTC positivity rate for patients having undergone resection of PM from CRC

Secondary

MeasureTime frame
Relationship of the CTC positivity rate with postoperative recurrence and prognosis

Countries

Japan

Contacts

Public ContactShinsuke Saisho

Kawasaki Medical School Department of General Thoracic Surgery

s.saisho@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026